Publications
HCCI’s external researcher publications powered by #HCCIdata

Apr
04

Insulin Prices in ESI Nearly Doubled from 2012-2021, with Effects of Emerging Biosimilars Evident in Recent Years

Insulin is a life-saving medication for millions of Americans who live with diabetes. As the price of insulin has risen, people who depend on insulin have had to make difficult decisions about whether to pay for their medication or other necessities. Some have been forced to ration their supply, with devastating results. Recent legislation has limited insulin out-of-pocket...

Continue reading
Tags:
Mar
30

Uptake of Biosimilars Remains Low Among People with Employer-Sponsored Insurance

Biologic drugs represent advances in medical research and treatment but are a major driver of drug spending in the United States. Spending on biologics increased by 50% between 2014 and 2018 in the U.S. even though just 2% of Americans used them. Biosimilars, clinically equivalent, lower-cost versions of original biologic drugs, analogous to generic versions of brand name "small molecule" drugs, c...

Continue reading
Mar
28

Rising Share of Chemotherapy Services Provided in Outpatient Departments is Associated with Higher Costs for Patients and Payers

Every year, 1 million people in the U.S. receive chemotherapy for cancer treatment. Most chemotherapy treatment requires patients to be present in a physician's office or hospital outpatient department to receive the treatment (typically an infusion or injection). Chemotherapy plays a critical role in treatment for many patients with cancer, but it also often leads to high financial costs for pati...

Continue reading
Mar
20

HCCI Spotlights Colorectal Cancer Awareness Month: Use of Cologuard Doubled over 2018-2020, Despite Drops Early in the COVID-19 Pandemic

Colorectal cancer screenings are essential for early disease detection, prevention, and treatment. Since 2014, Cologuard, a DNA-based screening test that can detect colorectal cancer and precancerous cells, has been available to individuals 45 and older at average risk for colorectal cancer. In contrast to colonoscopies, which must be done at a health care facility, Cologuard is non-invasive ...

Continue reading
Mar
17

HCCI Spotlights Colorectal Cancer Awareness Month: Colonoscopy Prep Drugs Underscore the Tradeoff Between Cost and Patient Preference

Colorectal cancer is the third most common cancer diagnosed in the U.S., and the second most common cause of cancer deaths among men and women combined. Screening via colonoscopy is highly effective in terms of improving prognosis of colorectal cancer via early detection; over 90% of patients who are diagnosed early (i.e., when the cancer is small and has not spread) live five years or l...

Continue reading